EGFR/EGFRvIII Inhibitor WSD0922-FU Clinical Trials

1 actively recruiting trial across 1 location

Also known as: BBB Penetrable EGFR/EGFRvIII Inhibitor WSD0922-FU, EGFR Mutant Inhibitor WSD0922-FU, WSD 0922-FU, WSD-0922-FU, WSD0922-FU

Pipeline

Phase 2: 1

Top Sponsors

Mayo Clinic1

Indications

Glioblastoma, IDH-Wildtype1
Cancer1

Scottsdale, Arizona1 trial

Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

Mayo Clinic in Arizona

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.